GET DAILY SIGNALSWhy Is Septerna (SEPN) Stock Down -2.18% Today?
Key Takeaways
- Shares fell about 2.18% (roughly $1.10) to around $49.64, down from Monday's close of $50.74.
- Primary catalyst: a post-earnings pullback after third-quarter 2026 results missed Wall Street consensus on both earnings and revenue.
- Secondary drivers: profit-taking following a sharp rally toward 52-week highs, plus a sizable jump in R&D spending that widened the quarterly loss.
- Broader context: a high-beta (≈2.2) clinical-stage biotech consolidating after a strong run, with sentiment shifting from momentum to fundamentals.
- What traders are watching next: SEP-479 Phase 1 data expected in Q1 2027, SEP-204 Phase 1 initiation, and Novo Nordisk collaboration milestones.
- For deeper context on valuation and analyst expectations, explore Price Targets, Earnings, and Forecast pages.
- To see how AI-driven strategies are positioning around this stock, explore Trending AI Robots.
Opening Summary
Septerna, Inc. (SEPN), a clinical-stage biotechnology company pioneering oral small-molecule drug discovery against G protein-coupled receptors (GPCRs), traded lower on Tuesday, retreating about 2.18% to roughly $49.64 after closing the prior session at $50.74. The decline — approximately $1.10 per share — follows the company's third-quarter 2026 earnings report, released after Monday's close, which came in below analyst expectations on both the top and bottom lines. The pullback marks a pause in what has been a powerful multi-month rally for the stock, which only recently touched a 52-week high.
Earnings-Driven Pullback After Q3 Miss
The dominant force behind Tuesday's move is the market's reaction to SEPN's third-quarter results. The company reported a net loss of $26.6 million, or $0.57 per share, versus a net profit of $8.2 million, or $0.18 per share, in the same quarter a year earlier. The loss per share came in wider than the roughly $0.42 loss analysts had anticipated, and revenue of $18.88 million fell short of the roughly $20.78 million consensus estimate. Research and development expenses surged more than 50% year over year to $36.6 million, reflecting the company's accelerating investment across its clinical pipeline, and the prior-year quarter had also benefited from a one-time gain on the sale of a non-financial asset that was absent this year.
Profit-Taking After a Sharp Rally
The earnings shortfall alone does not fully explain the price action; positioning also played a role. SEPN entered the report with strong momentum, having climbed from a 52-week low near $17.98 to a 52-week high above $51 within recent sessions — a rise of roughly 180%. With the stock trading near record territory and carrying an elevated beta, a modestly disappointing print gave short-term traders an obvious reason to lock in gains, producing a "sell-the-news" dynamic even as the company's longer-term pipeline narrative remained intact.
Positive Pipeline Updates Partially Offset the Miss
Not all of the news was negative. In conjunction with the results, Septerna highlighted the selection of SEP-204, an oral TSHR negative allosteric modulator, as a development candidate for Graves' disease and thyroid eye disease, with a Phase 1 trial planned for the first quarter of 2027. Management also reiterated that SEP-479 Phase 1 data for hypoparathyroidism is expected in Q1 2027 and noted progress under its Novo Nordisk collaboration in obesity and cardiometabolic diseases. These catalysts helped cushion the downside, keeping the decline measured rather than steep.
Market Context and Trading Activity
Trading activity remained active as investors digested the report, with volume running above the stock's recent average in the sessions surrounding the release. The move reflects a stock-specific, fundamentals-driven reaction rather than broad sector weakness, though the biotechnology space has shown choppiness as investors rotate among high-growth, high-beta names. The stock's consolidation near the low-to-mid $40s-to-$50s range leaves it well above key longer-term moving averages, underscoring how far it has rallied this year and why some near-term volatility was to be expected.
What Comes Next for SEPN
Looking ahead, the market's focus will shift back to clinical execution. Investors are watching for SEP-479 single- and multiple-ascending-dose data expected in the first quarter of 2027, the planned initiation of the SEP-204 Phase 1 trial, and continued advancement of partnered programs with Novo Nordisk. The company ended the quarter with $565.2 million in cash, cash equivalents, and marketable securities, which management expects to fund operations at least into mid-2029 — a balance-sheet cushion that reduces near-term financing risk. Key uncertainties remain the inherently binary nature of clinical readouts, rising operating expenses, and the potential for continued volatility given the stock's elevated beta and extended valuation.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing automated trading strategies. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving traders a range of approaches to explore. Visit Trending AI Robots to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for SEPN turns positive, indicating new upward trend
SEPN saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator turned positive. In 27 of the 28 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for SEPN just turned positive on October 20, 2026. Looking at past instances where SEPN's MACD turned positive, the stock continued to rise in 9 of 10 cases over the following month. The odds of a continued upward trend are 90%.
SEPN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SEPN crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 5 of 5 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +7.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where SEPN advanced for three days, in 88 of 99 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SEPN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
SEPN broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SEPN entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.896) is normal, around the industry mean (3.498). SEPN has a moderately low P/E Ratio (-92.170) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (17.361) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SEPN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SEPN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement